Prevention of contrast-induced AKI

A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial

Steven D. Weisbord, Martin Gallagher, James Kaufman, Alan Cass, Chirag Parikh, Glenn M. Chertow, Kendrick A. Shunk, Peter A. Mccullough, Michael J. Fine, Maria K. Mor, Robert A. Lew, Grant D. Huang, Todd A. Conner, Mary T. Brophy, Joanne Lee, Susan Soliva, Paul M. Palevsky

Research output: Contribution to journalArticle

Abstract

Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes. CI-AKI may be preventable because its risk factors are well characterized and the timing of renal insult is commonly known in advance. Intravenous (IV) fluids and N-acetylcysteine (NAC) are two of the most widely studied preventive measures for CI-AKI. Despite a multitude of clinical trials and meta-analyses, the most effective type of IV fluid (sodium bicarbonate versus sodium chloride) and the benefit of NAC remain unclear. Careful review of published trials of these interventions reveals design limitations that contributed to their inconclusive findings. Such design limitations include the enrollment of small numbers of patients, increasing the risk for type I and type II statistical errors; the use of surrogate primary endpoints defined by small increments in serum creatinine, which are associated with, but not necessarily causally related to serious, adverse, patient-centered outcomes; and the inclusion of low-risk patients with intact baseline kidney function, yielding low event rates and reduced generalizability to a higher-risk population. The Prevention of Serious Adverse Events following Angiography (PRESERVE) trial is a randomized, double-blind, multicenter trial that will enroll 8680 high-risk patients undergoing coronary or noncoronary angiography to compare the effectiveness of IV isotonic sodium bicarbonate versus IV isotonic sodium chloride and oral NAC versus oral placebo for the prevention of serious, adverse outcomes associated with CI-AKI. This article discusses key methodological issues of past trials investigating IV fluids and NAC and how they informed the design of the PRESERVE trial.

Original languageEnglish (US)
Pages (from-to)1618-1631
Number of pages14
JournalClinical Journal of the American Society of Nephrology
Volume8
Issue number9
DOIs
StatePublished - Jan 1 2013

Fingerprint

Acetylcysteine
Angiography
Sodium Bicarbonate
Sodium Chloride
Kidney
Multicenter Studies
Meta-Analysis
Creatinine
Biomarkers
Placebos
Clinical Trials
Serum
Population

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Prevention of contrast-induced AKI : A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. / Weisbord, Steven D.; Gallagher, Martin; Kaufman, James; Cass, Alan; Parikh, Chirag; Chertow, Glenn M.; Shunk, Kendrick A.; Mccullough, Peter A.; Fine, Michael J.; Mor, Maria K.; Lew, Robert A.; Huang, Grant D.; Conner, Todd A.; Brophy, Mary T.; Lee, Joanne; Soliva, Susan; Palevsky, Paul M.

In: Clinical Journal of the American Society of Nephrology, Vol. 8, No. 9, 01.01.2013, p. 1618-1631.

Research output: Contribution to journalArticle

Weisbord, SD, Gallagher, M, Kaufman, J, Cass, A, Parikh, C, Chertow, GM, Shunk, KA, Mccullough, PA, Fine, MJ, Mor, MK, Lew, RA, Huang, GD, Conner, TA, Brophy, MT, Lee, J, Soliva, S & Palevsky, PM 2013, 'Prevention of contrast-induced AKI: A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial', Clinical Journal of the American Society of Nephrology, vol. 8, no. 9, pp. 1618-1631. https://doi.org/10.2215/CJN.11161012
Weisbord, Steven D. ; Gallagher, Martin ; Kaufman, James ; Cass, Alan ; Parikh, Chirag ; Chertow, Glenn M. ; Shunk, Kendrick A. ; Mccullough, Peter A. ; Fine, Michael J. ; Mor, Maria K. ; Lew, Robert A. ; Huang, Grant D. ; Conner, Todd A. ; Brophy, Mary T. ; Lee, Joanne ; Soliva, Susan ; Palevsky, Paul M. / Prevention of contrast-induced AKI : A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. In: Clinical Journal of the American Society of Nephrology. 2013 ; Vol. 8, No. 9. pp. 1618-1631.
@article{8bea502e2f314ab880ce1c0e4bce50d7,
title = "Prevention of contrast-induced AKI: A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial",
abstract = "Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes. CI-AKI may be preventable because its risk factors are well characterized and the timing of renal insult is commonly known in advance. Intravenous (IV) fluids and N-acetylcysteine (NAC) are two of the most widely studied preventive measures for CI-AKI. Despite a multitude of clinical trials and meta-analyses, the most effective type of IV fluid (sodium bicarbonate versus sodium chloride) and the benefit of NAC remain unclear. Careful review of published trials of these interventions reveals design limitations that contributed to their inconclusive findings. Such design limitations include the enrollment of small numbers of patients, increasing the risk for type I and type II statistical errors; the use of surrogate primary endpoints defined by small increments in serum creatinine, which are associated with, but not necessarily causally related to serious, adverse, patient-centered outcomes; and the inclusion of low-risk patients with intact baseline kidney function, yielding low event rates and reduced generalizability to a higher-risk population. The Prevention of Serious Adverse Events following Angiography (PRESERVE) trial is a randomized, double-blind, multicenter trial that will enroll 8680 high-risk patients undergoing coronary or noncoronary angiography to compare the effectiveness of IV isotonic sodium bicarbonate versus IV isotonic sodium chloride and oral NAC versus oral placebo for the prevention of serious, adverse outcomes associated with CI-AKI. This article discusses key methodological issues of past trials investigating IV fluids and NAC and how they informed the design of the PRESERVE trial.",
author = "Weisbord, {Steven D.} and Martin Gallagher and James Kaufman and Alan Cass and Chirag Parikh and Chertow, {Glenn M.} and Shunk, {Kendrick A.} and Mccullough, {Peter A.} and Fine, {Michael J.} and Mor, {Maria K.} and Lew, {Robert A.} and Huang, {Grant D.} and Conner, {Todd A.} and Brophy, {Mary T.} and Joanne Lee and Susan Soliva and Palevsky, {Paul M.}",
year = "2013",
month = "1",
day = "1",
doi = "10.2215/CJN.11161012",
language = "English (US)",
volume = "8",
pages = "1618--1631",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "9",

}

TY - JOUR

T1 - Prevention of contrast-induced AKI

T2 - A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial

AU - Weisbord, Steven D.

AU - Gallagher, Martin

AU - Kaufman, James

AU - Cass, Alan

AU - Parikh, Chirag

AU - Chertow, Glenn M.

AU - Shunk, Kendrick A.

AU - Mccullough, Peter A.

AU - Fine, Michael J.

AU - Mor, Maria K.

AU - Lew, Robert A.

AU - Huang, Grant D.

AU - Conner, Todd A.

AU - Brophy, Mary T.

AU - Lee, Joanne

AU - Soliva, Susan

AU - Palevsky, Paul M.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes. CI-AKI may be preventable because its risk factors are well characterized and the timing of renal insult is commonly known in advance. Intravenous (IV) fluids and N-acetylcysteine (NAC) are two of the most widely studied preventive measures for CI-AKI. Despite a multitude of clinical trials and meta-analyses, the most effective type of IV fluid (sodium bicarbonate versus sodium chloride) and the benefit of NAC remain unclear. Careful review of published trials of these interventions reveals design limitations that contributed to their inconclusive findings. Such design limitations include the enrollment of small numbers of patients, increasing the risk for type I and type II statistical errors; the use of surrogate primary endpoints defined by small increments in serum creatinine, which are associated with, but not necessarily causally related to serious, adverse, patient-centered outcomes; and the inclusion of low-risk patients with intact baseline kidney function, yielding low event rates and reduced generalizability to a higher-risk population. The Prevention of Serious Adverse Events following Angiography (PRESERVE) trial is a randomized, double-blind, multicenter trial that will enroll 8680 high-risk patients undergoing coronary or noncoronary angiography to compare the effectiveness of IV isotonic sodium bicarbonate versus IV isotonic sodium chloride and oral NAC versus oral placebo for the prevention of serious, adverse outcomes associated with CI-AKI. This article discusses key methodological issues of past trials investigating IV fluids and NAC and how they informed the design of the PRESERVE trial.

AB - Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes. CI-AKI may be preventable because its risk factors are well characterized and the timing of renal insult is commonly known in advance. Intravenous (IV) fluids and N-acetylcysteine (NAC) are two of the most widely studied preventive measures for CI-AKI. Despite a multitude of clinical trials and meta-analyses, the most effective type of IV fluid (sodium bicarbonate versus sodium chloride) and the benefit of NAC remain unclear. Careful review of published trials of these interventions reveals design limitations that contributed to their inconclusive findings. Such design limitations include the enrollment of small numbers of patients, increasing the risk for type I and type II statistical errors; the use of surrogate primary endpoints defined by small increments in serum creatinine, which are associated with, but not necessarily causally related to serious, adverse, patient-centered outcomes; and the inclusion of low-risk patients with intact baseline kidney function, yielding low event rates and reduced generalizability to a higher-risk population. The Prevention of Serious Adverse Events following Angiography (PRESERVE) trial is a randomized, double-blind, multicenter trial that will enroll 8680 high-risk patients undergoing coronary or noncoronary angiography to compare the effectiveness of IV isotonic sodium bicarbonate versus IV isotonic sodium chloride and oral NAC versus oral placebo for the prevention of serious, adverse outcomes associated with CI-AKI. This article discusses key methodological issues of past trials investigating IV fluids and NAC and how they informed the design of the PRESERVE trial.

UR - http://www.scopus.com/inward/record.url?scp=84883711324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883711324&partnerID=8YFLogxK

U2 - 10.2215/CJN.11161012

DO - 10.2215/CJN.11161012

M3 - Article

VL - 8

SP - 1618

EP - 1631

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 9

ER -